(Q46886667)

26 December 2017

title

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research (English)

1 reference

26 December 2017

0 references

Elise M Pelletier

1

1 reference

26 December 2017

Paula J Smith

2

1 reference

26 December 2017

Kristina S Boye

3

1 reference

26 December 2017

Derek A Misurski

4

1 reference

26 December 2017

Sandra L Tunis

5

1 reference

26 December 2017

Michael E Minshall

6

1 reference

26 December 2017

publication date

1 January 2008

1 reference

26 December 2017

Applied Health Economics and Health Policy

published in

1 reference

26 December 2017

volume

6

1 reference

26 December 2017

issue

2-3

1 reference

26 December 2017

page(s)

103-112

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/bf03256126

exact match

0 references

cites work

Economic costs of diabetes in the U.S. In 2007.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Economic costs of diabetes in the US in 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Potential short-term economic benefits of improved glycemic control: a managed care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

The direct medical cost of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Direct medical costs of complications resulting from type 2 diabetes in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Guidelines for computer modeling of diabetes and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256126

21 January 2018

Identifiers

DOI

10.1007/BF03256126

1 reference

26 December 2017

1 reference

26 December 2017